

TOM DAVIS, VIRGINIA,  
CHAIRMAN

DAN BURTON, INDIANA  
CHRISTOPHER SHAYS, CONNECTICUT  
ILEANA ROS-LEHTINEN, FLORIDA  
JOHN M. McHUGH, NEW YORK  
JOHN L. MICA, FLORIDA  
MARK E. SOUDER, INDIANA  
STEVEN C. LATOURETTE, OHIO  
DOUG OSE, CALIFORNIA  
RON LEWIS, KENTUCKY  
JO ANN DAVIS, VIRGINIA  
TODD RUSSELL PLATT, PENNSYLVANIA  
CHRIS CANNON, UTAH  
ADAM H. PUTNAM, FLORIDA  
EDWARD L. SCHROCK, VIRGINIA  
JOHN J. DUNCAN, JR., TENNESSEE  
JOHN SULLIVAN, OKLAHOMA  
NATHAN DEAL, GEORGIA  
CANDICE MILLER, MICHIGAN  
TIM MURPHY, PENNSYLVANIA  
MICHAEL R. TURNER, OHIO  
JOHN R. CARTER, TEXAS  
WILLIAM J. JANKLOW, SOUTH DAKOTA  
MARSHA BLACKBURN, TENNESSEE

ONE HUNDRED EIGHTEEN CONGRESS

# Congress of the United States

## House of Representatives

COMMITTEE ON GOVERNMENT REFORM

2157 RAYBURN HOUSE OFFICE BUILDING

WASHINGTON, DC 20515-6143

MAJORITY (202) 225-5074  
FACSIMILE (202) 225-3974  
MINORITY (202) 225-5051  
TTY (202) 225-6852

[www.house.gov/reform](http://www.house.gov/reform)

November 19, 2003

HENRY A. WAXMAN, CALIFORNIA,  
RANKING MINORITY MEMBER

TOM LANTOS, CALIFORNIA  
MAJOR R. OWENS, NEW YORK  
EDOLPHUS TOWNS, NEW YORK  
PAUL E. KANJORSKI, PENNSYLVANIA  
CAROLYN B. MALONEY, NEW YORK  
ELIJAH E. CUMMINGS, MARYLAND  
DENNIS J. KUCINICH, OHIO  
DANNY K. DAVIS, ILLINOIS  
JOHN F. TIERNEY, MASSACHUSETTS  
WM. LACY CLAY, MISSOURI  
DIANE E. WATSON, CALIFORNIA  
STEPHEN F. LYNCH, MASSACHUSETTS  
CHRIS VAN HOLLEN, MARYLAND  
LINDA T. SANCHEZ, CALIFORNIA  
C.A. DUTCH RUPPERSBERGER,  
MARYLAND  
ELEANOR HOLMES NORTON,  
DISTRICT OF COLUMBIA  
JIM COOPER, TENNESSEE  
CHRIS BELL, TEXAS

BERNARD SANDERS, VERMONT,  
INDEPENDENT

The Honorable Thomas A. Scully  
Administrator  
Centers for Medicare and Medicaid Services  
200 Independence Avenue, SW  
Room 314-G  
Washington, DC 20201

Dear Mr. Scully:

I am writing regarding a recent regulatory proposal by HHS that changes recordkeeping requirements under the Medicaid program. The proposal, *Medicaid Program: Time Limitation on Price Recalculations and Recordkeeping Requirements under the Drug Rebate Program*,<sup>1</sup> would allow drug manufacturers to destroy records that could otherwise be used to uncover and punish Medicaid fraud. The proposed rule establishes a requirement that manufacturers must keep these records for three years, but then allows these records to be eliminated.

The proposed rule has been opposed by the Attorneys General of over 40 states, as well as the acting HHS Inspector General.<sup>2</sup> I share these concerns. As written, the proposal would make it easier for drug manufacturers to defraud the Medicaid system, potentially costing taxpayers billions of dollars.

Although the proposed rule does contain a provision that would prevent drug manufacturers from destroying records if they are aware of an investigation into their products, it fails to take into account that drug manufacturers are often unaware of investigations until they have been underway for several years.

HHS appears to be unaware of the potential problems of the rule. Indeed, in conversations with HHS staff who wrote the proposed rule, my staff was told that HHS was unaware of any fraud cases that reached back more than three years. In fact, there are many of these cases, in which federal and state governments have recovered billions of dollars from fraudulent manufacturers.

---

<sup>1</sup> 66 Fed. Reg. 51912 (Aug. 29, 2003).

<sup>2</sup> *Medicaid Records Proposal Criticized*, Associated Press (Nov. 10, 2003).

The Honorable Thomas A. Scully  
November 19, 2003  
Page 2


A November 2003 report prepared for the Taxpayers against Fraud Education Fund, which I have attached to this letter, highlights these cases.<sup>3</sup> The report identifies seven whistleblower cases in which the federal and state governments recovered \$1.7 billion in penalties against drug manufacturers who overcharged the Medicaid system for prescription drugs. In all but one of these cases, the length of time between the beginning of the fraudulent schemes and the settlement with the drug manufacturer was over three years. Often, the period during which the fraud occurred was well over three years — in one case, up to 12 years.

The findings in this report make it abundantly clear that allowing drug manufacturers to destroy Medicaid pricing records after just three years could make it easier for an unscrupulous drug manufacturer to defraud the Medicaid system and to avoid full recompense if they are apprehended, with huge costs to taxpayers.

In light of these problems, I am asking that you rewrite this proposed rule. Presently, the False Claims Act has a statute of limitations of up to 10 years. Changes to the proposed rule that take this statute of limitations into account and require that manufacturers maintain records for at least a ten-year period would serve to adequately protect taxpayers and the Medicaid program.

Thank you for your attention to this issue. If there are any questions about this letter, my staff contact is Brian Cohen at (202) 225-5051.

Sincerely,

  
Henry A. Waxman  
Ranking Minority Member

Enclosure

---

<sup>3</sup> Taxpayers against Fraud Education Fund, *Reducing Medicare and Medicaid Fraud by Drug Manufacturers: The Role of the False Claims Act* (Nov. 2003).